Abstract

Rapid development of genomic studies has led to development of new molecular biomarkers for diagnosis of primary and recurrent forms of bladder cancer. The study objective is to evaluate the current status of molecular biomarkers for diagnosis of recurrence and/or progression of bladder cancer and possibilities of their clinical use. A search of literature published in the last several years in the Pubmed and MedLine databases was performed. The obtained data was analyzed, sensitivity, specificity, positive and negative prognostic value were determined. The requirements for quality and characteristics of molecular biomarkers vary significantly depending on a specific case. The clinical role of urine biomarkers in observation of patients with nonmuscle invasive bladder cancer remains uncertain. Assays approved by the U.S. Food and Drug Administration do not demonstrate desired sensitivity and specificity which leads to their limited use. Currently, commercial assays of urine biomarkers are not sufficiently studied which predetermines further search for the optimal method of early diagnosis of bladder cancer. Multicenter clinical studies will allow to determine the place of each molecular biomarker in clinical practice.

Highlights

  • Rapid development of genomic studies has led to development of new molecular biomarkers for diagnosis of primary and recurrent forms of bladder cancer

  • The study objective is to evaluate the current status of molecular biomarkers for diagnosis of recurrence and/or progression of bladder cancer and possibilities of their clinical use

  • The requirements for quality and characteristics of molecular biomarkers vary significantly depending on a specific case

Read more

Summary

Introduction

Цистоскопия, общепринятая в качестве «золотого стандарта» обнаружения РМП, является инвазивной процедурой, сопряженной с риском развития инфекционных осложнений, в то время как цитологическое исследование мочи имеет высокую чувствительность (84 %) лишь при опухолях высокой степени злокачественности. С учетом низкой чувствительности цитологического исследования мочи, а также временных и иногда финансовых ограничений, связанных с проведением цистоскопии, были разработаны и внедрены в клиническую практику многочисленные биомаркеры в моче. У ряда биомаркеров, одобренных Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США, не определена степень клинической значимости, что ограничивает их использование, особенно при наблюдении за пациентами с риском прогрессирования и / или рецидива РМП [4].

Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call